Matrix Laboratories Limited
Add to watch list to get report alerts
BSE Code:
524794
NSE Code:
MATRIXLABS
Business Profile
Business Profile
Matrix Laboratories is engaged in the manufacture of active pharmaceutical ingredients (APIs) and solid oral dosage forms. The company was incorporated on Nov. 29, 1984, was converted into a public limited company on Oct. 19, 1992, and got its current name on March 21, 2001.
The company manufactures APIs in anti bacterials like Ciproflaxin, Gatifloxacin, Norfloxacin, etc; CNS agents like Citalopram, Sertraline, Ropinirole, etc; anti histamine/anti asthamatics like Loratadine, Cetirizine, etc; cardio vasculars like Amlodipine and its salts, Perindopril, etc; anit virals like Acyclovir, Zidovudine, etc; anti diabetics like Nateglinide; anti fungals like Fluconazole, Terbinafine, etc; proton pump inhibitors like Omeprazole, Lansoprazole, etc; Celecoxib and Rizatriptan, etc, for pain management; and others like Sibutramine, Tamsulosin, etc. Drugs under development include CNS agents like Quetiapine, Escitalopram, etc. The four manufacturing facilities are located near Hyderabad and Visakhapatnam. The solid oral dosage forms facility is located near Nasik. The facilities have ISO 9000 and ISO 14000 Certifications.
Matrix Laboratories has an agreement with the Clinton HIV/AIDS Initiative (CHAI), where the prices of AIDS treatment drugs will be lowered. The affordable second-line ARV drugs will move into 66 low-and middle-income countries in Africa, Asia, Latin America and the Caribbean. The company is to acquire residual holding of Mark Gao, the erstwhile promoter of Mchem Group of companies of China. The company has a 60% equity stake in the MChem group.
The company offers contract research and development services during early stages of development and contract manufacturing for projects that have advanced further into development and are being considered for commercial manufacturing. The registered office of the company is located at 1-1-151/1, Sairam Towers, IVth Floor, Alexander Road, Secunderabad-500003, Andhra Pradesh.
Financials
The company reported a small rise in standalone net profit for the quarter ended December 2008. During the quarter, the profit of the company rose 5.21% to Rs 361.40 million from Rs 343.49 million in the same quarter previous year. Net sales for the quarter surged 59.52% to Rs 3,961.30 million, while total income for the quarter jumped 59.65% to Rs 4,030 million, when compared with the prior year period. It reported earnings of Rs 2.34 a share during the quarter, registering 4.93% growth over prior year period.
Recent Developments
31-MAR-09
The company received the first tentative approval from the U.S Food and Drug Administration (FDA) under the President`s Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 200 mg/300 mg.
12-MAR-09
The company has received a tentative approval for Lopinavir / Ritonavir Tablets 200/50 mg from US Food & Drug Administration (USFDA) under the president`s emergency plans for AIDS relief (PEPFAR).